Short interest for Eterna Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Eterna Therapeutics's stock. Short interest data is updated every two weeks.

Eterna Therapeutics Stock (NASDAQ:ERNA), Short Interest Report

Eterna Therapeutics

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Biotech

News

Penny Stocks

Health Care

Market-Moving Exclusives

Exclusives

General

ERNA

LCTX

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ: 

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Contracts

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ: ERNA) for beta 2 microglobulin (B2M)-deficient induced plurip

EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology

Insider Trades

Movers

Trading Ideas

Eterna Therapeutics Inc (NASDAQ: ERNA) shares initially surged Wednesday morning on recent insider buying, but the stock pulled back shortly after the market open.

What&#39;s Going On With Eterna Therapeutics Stock Today?

Eterna Therapeutics Inc

Diverse Team of Financial and Legal Executives Brings Expertise Across Energy Industry
RONAN, Mont., May 7, 2024 /PRNewswire/ -- Montana Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) ("Montana"), the developer of AirJoule&#xAE;, a transformational atmospheric thermal energy and water harvesting technology, announced today that it has appointed the following financial and legal executives to its management team:
<ul>
<li>Stephen Pang, Chief Financial Officer;</li>
<li>Chad&nbsp;MacDonald, Chief Legal Officer; and</li>
<li>Tom Divine, Vice President, Investor Relations and Finance</li>
</ul>
In conjunction with these new appointments, Jeff Gutke, who since 2021 served as the Chief Financial Officer of Montana's predecessor company, Montana Technologies LLC, is transitioning into the new role of Chief Administrative Officer at Montana. The management team will also include Pat Eilers, the Chairman of Montana's Board of Directors, who has been named Montana's Executive Chairman.&nbsp;
Matt Jore, Chief Executive Officer and Director of Montana, said, "I am thrilled to welcome Stephen, Chad, and Tom to the Montana&nbsp;team. Collectively, they bring a wealth of knowledge and public company experience, serving as critical additions as we continue to scale our operations&nbsp;and progress in responding to the increasing global demand for water and air conditioning. I would also like to thank Jeff for his immense dedication and hard work over the last three years, and I am&nbsp;delighted that he can now amplify his focus on the most critical administrative functions required of our newly public company."
Pat Eilers, Executive Chairman, said, "Adding a strong&nbsp;management team to our outstanding technology team is key to accomplishing the ambitious and important work that lies ahead for Montana. We&nbsp;look forward to capitalizing&nbsp;on each member's expertise and skillset, and we are confident that they will play a significant role as we continue to advance AirJoule&#xAE; toward wider commercial adoption."

Management

AIRJ

Montana Technologies Appoints Stephen Pang As Chief Financial Officer

Barings BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDC#NYSE">BBDC</a>) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $0.30 by 6.67 percent. This is a 12 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $69.807 million which missed the analyst consensus estimate of $73.517 million by 5.05 percent. This is a 3.87 percent increase over sales of $67.204 million the same period last year.

Earnings

Earnings Misses

BBDC

Barings BDC Q1 2024 GAAP EPS $0.28 Misses $0.30 Estimate, Sales $69.807M Miss $73.517M Estimate

Guidance

TMCI

Treace Medical Concepts Sees FY24 Revenue $201M-$211M Vs $222.815M Est.

Planet Green Holdings Corp. ("Planet Green Holdings" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLAG#NYSE">PLAG</a>) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended&nbsp;December 31, 2023, which was filed on&nbsp;April 1, 2023&nbsp;with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 to the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended&nbsp;December 31, 2023.

PLAG

Planet Green Holdings Received Audit Opinion With Going Concern Explanation

SWIM

Latham Group Sees FY24 Net Sales $490M-$520M vs $505.93M Est.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.graniteconstruction.com%2F&amp;esheet=53957454&amp;newsitemid=20240502848700&amp;lan=en-US&amp;anchor=Granite&amp;index=1&amp;md5=454bceeced194171df2566482108c1ff">Granite</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GVA#NYSE">GVA</a>) announced the opening of its new office in Ontario, California. This strategic move marks Granite's commitment to serving the Inland Empire and further solidifying its position in the market.
Located in the heart of the Inland Empire, Granite's Ontario office will serve as a hub for Granite's operations in the region. With this expansion, Granite aims to enhance its local presence, foster stronger relationships with clients, and contribute to the region's growth.
<ul>
<li>Infrastructure Connection: The Inland Empire is a vital corridor connecting Moreno Valley to Los Angeles. By establishing an office here, Granite aims to enhance this critical infrastructure link, facilitating smoother transportation and connectivity for residents and businesses.</li>
<li>Market Expertise: "Our commitment to growing our expertise in the market is unwavering," says Bill Moore, Granite's Vice President of Regional Operations. "The establishment of our new office is in alignment with Granite's plan to secure more projects in the Inland Empire."</li>
<li>Project Pipeline: Granite's presence in the Inland Empire positions it to participate in upcoming infrastructure projects. The company's track record of safety, quality, and sustainability makes it a trusted partner for public and private clients alike.</li>
</ul>
After successfully completing the $17 million Perris Logistics Center North project and the $22 million <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.graniteconstruction.com%2Fnewsroom%2Fgranite-secures-22-million-metrolink-station-expansion-project&amp;esheet=53957454&amp;newsitemid=20240502848700&amp;lan=en-US&amp;anchor=Metrolink+Station+Expansion&amp;index=2&amp;md5=d6b1e9b88c38d644bc0702136c3084b5">Metrolink Station Expansion</a>, Granite will begin construction on the $25 million Hub at Ontario in June 2024.
Granite's investment in the Inland Empire is a testament to its dedication to local communities. Not only is Granite creating jobs and supporting local suppliers, but it's also contributing to infrastructure development. Furthermore, Granite is committed to fostering a robust hiring and recruiting process and encourages candidates to explore opportunities on its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.graniteconstruction.com%2Fcareers&amp;esheet=53957454&amp;newsitemid=20240502848700&amp;lan=en-US&amp;anchor=career+page&amp;index=3&amp;md5=83e2deb582b9f7dfc8075064e0cbba9f">career page</a>. This initiative aims to bring in local talent, providing them with opportunities for growth and development. By doing so, Granite hopes to be a positive force

Granite Construction Expands Presence In Inland Empire, California; Granite Will Begin Construction On The $25M Hub At Ontario In June 2024

PubMatic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.11) by 181.82 percent. The company reported quarterly sales of $66.701 million which beat the analyst consensus estimate of $62.182 million by 7.27 percent. This is a 20.38 percent increase over sales of $55.407 million the same period last year.

Earnings Beats

PUBM

PubMatic Q1 2024 Adj EPS $0.09 Beats $(0.11) Estimate, Sales $66.701M Beat $62.182M Estimate

Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.12) by 32.14 percent. This is a 81.14 percent increase over losses of $(4.03) per share from the same period last year. The company reported quarterly sales of $20.214 million which beat the analyst consensus estimate of $19.445 million by 3.96 percent. This is a 42.05 percent decrease over sales of $34.879 million the same period last year.

ATER

Aterian Q1 2024 GAAP EPS $(0.76) Beats $(1.12) Estimate, Sales $20.214M Beat $19.445M Estimate

SMWB

Similarweb Expects Q2 Total Revenue Of $60M-$60.5M (Est $60.313M), Continues To Expect Total Revenue Of $242M-$246M  (Est $249.82M)

Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) reported $1.03 million in sales this quarter. This is a 11.66 percent decrease over sales of $1.17 million the same period last year.

VLCN

Volcon Q1 Sales $1.03M Down From $1.17M YoY

The criminal trial of former President Donald Trump <a href="https://www.benzinga.com/news/24/02/37053113/trump-claims-unfair-treatment-in-classified-documents-case-if-biden-is-not-going-to-be-charged-then">regarding classified documents</a> has been postponed indefinitely by a federal judge.
What Happened: The trial, which was set to begin on May 20, has been postponed indefinitely, as per a court filing on Tuesday, <a href="https://www.cnbc.com/2024/05/07/trump-classified-documents-trial-postponed-indefinitely.html">reported</a> CNBC. 
The charges against Trump include the willful retention of classified national security records after his tenure at the White House, followed by their concealment from federal authorities.
See Also: <a href="https://www.benzinga.com/news/24/05/38630517/trumps-niece-says-ex-president-has-made-it-clear-he-wants-to-be-authoritarian-upon-returning-to-offi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Niece Says Ex-President Has Made It Clear He Wants To Be Authoritarian Upon Returning To Office:</a>
U.S. District Judge Aileen Cannon stated in the court order that it would be imprudent to set a trial date at this point due to unresolved pre-trial issues. These include concerns about the handling of classified information in the high-profile trial of the former president and the additional pre-trial and trial preparations required to present the case to a jury.
Proceeding with the trial in May would be &#8220;inconsistent with the Court&#8217;s duty to fully and fairly consider&#8221; these issues, Cannon wrote. The current trial date of May 20, has been vacated, with a new date to be set following the resolution of these matters.
Why It Matters: Judge Cannon was appointed to the federal bench by Trump in 2020.
Her drawing out the case for over 10 months has observers and political commentators scrutinizing what they say should have been a routine procedure thus far.
The postponement of Trump&#8217;s trial also comes amid a charged political climate. In a recent podcast episode, Nobel laureate Joseph Stiglitz voiced his apprehension about the potential consequences of a second term for Trump. He asserted it would be detrimental to <a href="https://www.benzinga.com/news/24/05/38662455/nobel-laureate-joseph-stiglitz-warns-reelection-of-trump-would-be-a-disaster">democracy and social justice.</a>
Stiglitz, during his appearance on the "In the City" podcast, also expressed his concerns over the misuse of the term &#8216;freedom&#8217; by the political right. He believes this misuse is diminishing the freedoms of most people.
Read Next: <a href="https://www.benzinga.com/news/24/05/38668133/xi-jinping-says-he-would-never-forget-natos-bombing-of-chinese-embassy-25-years-ago-will-never-allow?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Xi Jinping Says He Would &#8216;Never Forget&#8217; NATO&#8217;s Bombing Of Chinese Embassy 25 Years Ago: &#8216;Will Never Allow</a>
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

Politics

Legal

Federal Judge Indefinitely Postpones Donald Trump's Classified Documents Trial

loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.06) by 100 percent. This is a 36.84 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $222.785 million which missed the analyst consensus estimate of $231.560 million by 3.79 percent. This is a 7.16 percent increase over sales of $207.901 million the same period last year.

loanDepot Q1 2024 Adj EPS $(0.12) Misses $(0.06) Estimate, Sales $222.785M Miss $231.560M Estimate

REAL

The RealReal Sees Q2 Total Revenue $135M-$145M vs $139.45M Est., FY24 Total Revenue $580M-$605M vs $589.13M Est.

ICUI

ICU Medical Sees FY24 Adj. EPS $4.40-$5.10 Vs $4.730 Est.

SandRidge Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SD#NYSE">SD</a>) reported quarterly earnings of $0.30 per share. This is a 53.13 percent decrease over earnings of $0.64 per share from the same period last year. The company reported $30.28 million in sales this quarter. This is a 29.81 percent decrease over sales of $43.15 million the same period last year.

SandRidge Energy Q1 Adj $0.30 Down From $0.64 YoY, Sales $30.28M Down From $43.15M YoY

The Company is reiterating its 2024&nbsp;outlook&nbsp;for full year Adjusted EBITDA between&nbsp;$(20)&nbsp;million&nbsp;and&nbsp;$(10)&nbsp;million. The Company still expects its quarterly revenue and adjusted EBITDA performance to improve sequentially as it progresses through the year with adjusted EBITDA projected to be positive for the second half of 2024.

PRPL

Purple Innovation Reiterates FY24 Net Revenue Outlook Of $540M-$560M, Est $548.909M

QTRX

Quanterix Sees FY24 Revenue $139M-$144M Vs $141.739M Est.

Clipper Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLPR#NYSE">CLPR</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.12 by 16.67 percent. This is a 27.27 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $35.760 million which missed the analyst consensus estimate of $36.008 million by 0.69 percent. This is a 6.22 percent increase over sales of $33.667 million the same period last year.

CLPR

Clipper Realty Q1 2024 FFO $0.14 Beats $0.12 Estimate, Sales $35.760M Miss $36.008M Estimate

Ichor Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of undefined by Infinity percent. This is a 123.68 percent decrease over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $201.383 million which beat the analyst consensus estimate of $199.986 million by 0.70 percent. This is a 10.84 percent decrease over sales of $225.870 million the same period last year.

ICHR

Ichor Hldgs Q1 2024 Adj EPS $(0.09) Misses undefined Estimate, Sales $201.383M Beat $199.986M Estimate

Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) reported its first-quarter financial results after the bell Tuesday. Here's a<a href="https://www.benzinga.com/pressreleases/24/05/b38681381/virgin-galactic-announces-first-quarter-2024-financial-results-and-provides-business-update"> look at the highlights. </a>
The Details: Virgin Galactic reported quarterly losses of 25 cents per share which beat the analyst consensus estimate of losses of 29 cents by 13.79%.
Quarterly sales came in at $2 million which beat the analyst consensus estimate of $1.92 million by 4.28% and represented a 410.2 % increase over sales of $392,000 from the same period last year.
The company said its spaceship final assembly facility in Arizona is on track to open in summer 2024, and its production schedule for the Delta Class spaceships remains on track for revenue service in 2026. VMS Eve is expected to support an increased flight rate of up to 125 flights per year and have an annualized run-rate of $450 million in revenue with the first two Delta Class spaceships.
&#8220;It&#8217;s an exciting time for Virgin Galactic as we celebrate the success of VSS Unity with its upcoming &#8216;Galactic 07&#8217; mission and remain laser-focused on executing our Delta Class program. Tool delivery and parts fabrication are beginning to accelerate as we work to complete the bulk of the Delta design phase this summer and move more fully into the build phase. We remain on track for commercial service in 2026,&#8221; said Michael Colglazier, CEO of Virgin Galactic.
Outlook:  Virgin Galactic expects revenue for the second quarter to be approximately $3.5 million and free cash flow to be in the range of negative $110 million to negative $120 million.
Related News: <a href="https://www.benzinga.com/news/earnings/24/05/38653933/hims-hers-health-reports-better-than-expected-q1-results-strong-guidance">Hims &amp; Hers Health Reports Better-Than-Expected Q1 Results, Strong Guidance</a>
SPCE Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Virgin Galactic shares are down 4.85% after-hours at 96 cents at the time of publication Tuesday.
Photo: Shutterstock

SPACE

After-Hours Center

SPCE

Virgin Galactic Reports Better-Than-Expected Q1 Results

Eterna Therapeutics files to sell 18.2M shares for holders

Eterna Therapeutics (ERNA) has released an update. Eterna Therapeutics Inc. has appointed Mr. Peter Cicala to its Board of Directors, where he will...

Eterna Therapeutics Welcomes New Board Member Peter Cicala

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eterna Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) just reported results for the fourth quarter of 2023.<ul><li>Eterna Therapeutics reported earnings per share of -$1.14.</li><li>The company reported revenue of $17,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/erna-stock-earnings-eterna-therapeutics-for-q4-of-2023/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Intuitive Surgical (NASDAQ:<a href="https://investorplace.com/stock-quotes/isrg-stock-quote/">ISRG</a>) stock is getting a boost on Friday as investors celebrate <a href="https://finance.yahoo.com/news/intuitive-announces-fda-clearance-fifth-203000634.html">approval of da Vinci 5</a> by the Food and Drug Administration (FDA).



Da Vinci 5 is the next generation of Intuitive Surgical&rsquo;s multiport robotic system that has been used in more than 7 million procedures. The newest version brings with it increased performance, an enhanced 3D imaging system and new Force Feedback technology.



Myriam J. Curet, M.D., Chief Medical Officer of Intuitive Surgical, said the following about the da Vinci 5.




&ldquo;We strive to provide customers with technology that meets their needs and solves important problems. We intend to launch da Vinci 5 more broadly in the U.S. and globally after we learn from and work with an initial smaller number of customers directly.&rdquo;




Investors looking for more details about the da Vinci 5 launch will get them on Monday. The company plans to hold a conference call before markets open that day to discuss its plans.



<h2>How This Affects ISRG Stock Today</h2>



ISRG stock started off normal trading hours this morning with more than 582,000 shares traded. The company&rsquo;s daily average trading volume is about 1.6 million shares.



ISRG stock is up 1.3% as of Fridya morning.



Investors can check out more of the latest stock market stories today below!



We have all of the hottest stock market news worth reading about on Friday! Among that is what has shares of Rivian&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>), Kopin&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kopn-stock-quote/">KOPN</a>) and Eterna Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) stock moving today. All of that info is ready to go at the following links!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/piper-sandler-just-raised-its-price-target-on-rivian-rivn-stock/">Piper Sandler Just Raised Its Price Target on Rivian (RIVN) Stock</a></li>



<li><a href="https://investorplace.com/2024/03/why-is-kopin-kopn-stock-down-15-today/">Why Is Kopin (KOPN) Stock Down 15% Today?</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/erna-stock-earnings-eterna-therapeutics-for-q4-of-2023/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023</a></li>
</ul> On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/isrg-stock-alert-the-fda-is-giving-intuitive-surgical-a-big-boost/">ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Intuitive Surgical (NASDAQ:<a href="https://investorplace.com/stock-quotes/isrg-stock-quote/">ISRG</a>) stock is getting a boost on Friday as investors celebrate <a href="https://finance.yahoo.com/news/intuitive-announces-fda-clearance-fifth-203000634.html">clearance of the da Vinci 5</a> from the U.S. Food and Drug Administration (FDA).



Da Vinci 5 is the next generation of Intuitive Surgical&rsquo;s multiport robotic system that has been used in more than 7 million procedures. The newest version brings with it increased performance, an enhanced 3D imaging system and new Force Feedback technology.



Myriam J. Curet, M.D., Chief Medical Officer of Intuitive Surgical, said the following about the da Vinci 5:




&ldquo;We strive to provide customers with technology that meets their needs and solves important problems [&hellip;] We intend to launch da Vinci 5 more broadly in the U.S. and globally after we learn from and work with an initial smaller number of customers directly.&rdquo;




Investors looking for more details about the da Vinci 5 launch will get them on Monday. The company plans to hold a conference call before markets open that day to discuss its plans.



<h2>How This Affects ISRG Stock Today</h2>



ISRG stock started off normal trading hours this morning with more than 582,000 shares traded. The company&rsquo;s daily average trading volume is about 1.6 million shares.



ISRG stock is up 1.3% as of Fridya morning.



Investors can check out more of the latest stock market stories today below!



We have all of the hottest stock market news worth reading about on Friday! Among that is what has shares of Rivian&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>), Kopin&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kopn-stock-quote/">KOPN</a>) and Eterna Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) stock moving today. All of that info is ready to go at the following links!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/piper-sandler-just-raised-its-price-target-on-rivian-rivn-stock/">Piper Sandler Just Raised Its Price Target on Rivian (RIVN) Stock</a></li>



<li><a href="https://investorplace.com/2024/03/why-is-kopin-kopn-stock-down-15-today/">Why Is Kopin (KOPN) Stock Down 15% Today?</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/erna-stock-earnings-eterna-therapeutics-for-q4-of-2023/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023</a></li>
</ul>On the date of publication, William White&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/isrg-stock-alert-the-fda-is-giving-intuitive-surgical-a-big-boost/">ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eterna Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) just reported results for the fourth quarter of 2023.<ul><li>Eterna Therapeutics reported earnings per share of -$1.14.</li><li>The company reported revenue of $17,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/erna-stock-earnings-eterna-therapeutics-for-q4-of-2023/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more

AGRX

AMPE

APTO

AQMS

AREC

ASTS

ATNM

AULT

AXDX

AYRO

BLRX

BZFD

CMCL

CTAS

CWCO

DARE

DCTH

DLNG

DNMR

DOMH

DOYU

DTIL

ESLT

GLPG

GREE

HEPS

IDEX

ISRG

ITRM

KOPN

LGMK

LITB

MAXN

MDAI

NCNO

NVVE

OGEN

ORGS

OUST

PAYS

PAYX

PLBY

REKR

RIVN

RKDA

SMTC

STIX

TIVC

VIOT

VRNT

VSTM

VUZI

WPRT

XELA

XXII

Financing

Press Releases

Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Markets

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Eterna Therapeutics Stock (NASDAQ:ERNA), Short Interest Report

People Also Watch